Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
Study finds that patients with IBD and 1 or more comorbidities are at increased risk for viral or bacterial meningitis.
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
A team of investigators assessed the accuracy of a machine learning model in grading the severity of ulcers in patients with Crohn disease.
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Probiotics should only be recommended for specific patient populations since there is not enough evidence to support their use in the majority of digestive conditions, according to new clinical guidelines released by the American Gastroenterological Association (AGA) and recently published in Gastroenterology.
Steroid-sparing therapy may reduce risk for PFCs in young patients with Crohn disease
Variation in fecal calprotectin levels after ileocolonic resection is an accurate predictor of early endoscopic POR in patients with Crohn’s disease.
According to results from a large cohort validation study, IBD-Disk was reported to be both viable and reliable.
Researchers assessed the microbial profiles of patients with IBD with recurrent C. difficile infection.
There is significant interest in optimizing medical treatments of Crohn’s disease (CD) in hopes of preventing complications and the need for surgery.
Measurement of fecal volatile organic compounds (VOC) was effective in identifying inflammatory bowel disease (IBD) biomarkers, but not for monitoring disease activity.
Certain enteric pathogens are associated with higher risk of incident inflammatory bowel disease, while others are could be protective.
Higher infliximab trough levels were associated with clinical and endoscopic remission in patients with Crohn disease (CD), according to a substudy.
Adalimumab, an anti-Tumor Necrosis Factor alpha (TNFα) antibody, may be effective in managing inflammatory bowel disease symptoms in patients with COVID-19.
An international team of investigators conducted a follow-up to the CALM study to assess the impact of early disease remission in individuals with Crohn disease.
Older age is associated with an increased risk for bacteremia in hospitalized patients with inflammatory bowel disease.
Deep early remission of Crohn disease is associated with a significant decrease in long-term adverse effects.
A panel of serum biomarkers was found to identify patients who will develop Crohn disease up to 5 years before diagnosis.
In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.